Back to search

Netherlands· NL-c8bb2687413b

Sofradex, oordruppels

A dexamethason und antiinfektiva product containing dexamethason natriummetasulfobenzoaat + framycetinesulfaat + gramicidine, registered in Netherlands by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 6 of our 19 countries.

ATC S02CA06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedSofradex, oordruppelsATCS02CA06REGISTER NO.NL-c8bb2687413bPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Dexamethason und antiinfektiva is registered in 6 of 19 countries.

Countries holding a registration under ATC S02CA06 (dexamethason und antiinfektiva), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 3 of them publish a price we can compare per daily dose

Dexamethason und antiinfektiva · ATC S02CA06

6 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DEXAMETHASON NATRIUMMETASULFOBENZOAAT + FRAMYCETINESULFAAT + GRAMICIDINE
Manufacturer
CHEPLAPHARM Arzneimittel GmbH
Country
Netherlands (NL)
ATC code
S02CA06
ATC class
Dexamethason und Antiinfektiva
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    04961

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under S02CA06

Dexamethason und antiinfektiva, as other registers publish it.

All dexamethason und antiinfektiva products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • United Kingdom (Northern Ireland) · Sofradex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c33a8e56-3b5c-4fd5-b07a-6042fb1f701a
GET /v1/drugs/c33a8e56-3b5c-4fd5-b07a-6042fb1f701a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oordruppels, oplossing",
  "route": "Auriculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h04961_smpc.pdf",
  "strength": null,
  "atc_label": "Dexamethasone And Antiinfectives",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg04961",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "ETHANOL, GEDENATUREERD MET METHANOL",
    "FENETHYLALCOHOL",
    "LITHIUM CHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "POLYSORBAAT 80 (E 433)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "DEXAMETHASON NATRIUMMETASULFOBENZOAAT",
    "FRAMYCETINESULFAAT",
    "GRAMICIDINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h04961.pdf",
  "authorised_at": "1966/01/14",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "04961",
  "additional_monitoring": "N"
}

See everything about dexamethason und antiinfektiva.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.